---
title: "CR Double-Crane's subsidiary's peritoneal dialysis solution (lactate) series of drugs has received the approval notice for the drug supplementary application"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/256877687.md"
description: "CR Double-Crane's wholly-owned subsidiary Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. recently received the approval notice for the supplementary application of peritoneal dialysis solution (lactate-G1.5% and G2.5%) issued by the National Medical Products Administration. This approval will help enhance the sales and competitiveness of this series of drugs in the market, primarily used for the treatment of patients with acute and chronic renal failure"
datetime: "2025-09-11T08:55:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/256877687.md)
  - [en](https://longbridge.com/en/news/256877687.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/256877687.md)
---

# CR Double-Crane's subsidiary's peritoneal dialysis solution (lactate) series of drugs has received the approval notice for the drug supplementary application

According to the Zhitong Finance APP, CR Double-Crane (600062.SH) announced that its wholly-owned subsidiary Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. (referred to as "Shanghai Changfu") has recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration (referred to as "NMPA") for peritoneal dialysis solution (lactate-G1.5%) and peritoneal dialysis solution (lactate-G2.5%) (referred to as "this series of drugs").

Peritoneal dialysis solution (lactate) is mainly suitable for patients with acute and chronic renal failure who require continuous non-bedside peritoneal dialysis treatment due to ineffective non-dialysis treatment. The acquisition of this "Drug Supplement Application Approval Notice" is a further supplement to the specifications of peritoneal dialysis solution (lactate), which will help to unleash the potential for future market sales and market competition of this series of drugs

### Related Stocks

- [600062.CN](https://longbridge.com/en/quote/600062.CN.md)

## Related News & Research

- [Guriev: Russia is in need of a pipeline to China](https://longbridge.com/en/news/286935918.md)
- [Oil little changed as traders await breakthrough in US.-Iran negotiations](https://longbridge.com/en/news/286925961.md)
- [International Energy Agency Is Wrong To Forecast Coal's Demise](https://longbridge.com/en/news/286899857.md)
- [10:19 ETAARC-360 Completes AICPA Peer Review with Pass Rating](https://longbridge.com/en/news/286929747.md)
- [Russia plans to return staff to Iranian Bushehr nuclear plant in coming weeks, RIA reports](https://longbridge.com/en/news/286905394.md)